纳米抗体与小型蛋白支架文献周报

检索日期：2026年7月15日 覆盖时间：2026年7月8日 — 2026年7月15日（过去7天新收录文献） 检索数据库：PubMed (NCBI E-utilities API)检索式：基于用户指定检索策略，涵盖nanobody/VHH/FN3/affibody/DARPin/anticalin/knottin等 纳入标准：JCR Q1/Q2 或 SCI 1/2区期刊 | 以纳米抗体/小型蛋白支架为核心研究对象 排除标准：传统mAb/IgG/Fab/scFv为主线的研究 | FNDC5/irisin等天然蛋白 | 综述/评论/预印本（除非高质量期刊）

本周检索结果概览：PubMed检索命中50篇，经主题聚焦筛选后保留26篇，其中Q1/Q2高质量期刊文献21篇（A级推荐9篇，B级推荐10篇，C级推荐2篇），待核验文献5篇，排除假阳性4篇（FNDC5/irisin/ELFN2天然蛋白）。

一、本周高质量文献列表

二、逐篇文献解读

文献 1

英文题目： Anti-amyloid nanobody-Fc fusion protein drives potent amyloid clearance through microglial recruitment.中文题目：抗淀粉样蛋白纳米抗体-Fc融合蛋白通过小胶质细胞募集驱动高效淀粉样蛋白清除作者：Ding Zonghui, Gibson Katelin A, Nascari David G, et al.期刊：Alzheimer's & dementia (New York, N. Y.) (Alzheimers Dement (N Y))发表时间：PMID：42444752DOI：10.1002/trc2.70269PubMed 链接：https://pubmed.ncbi.nlm.nih.gov/42444752/期刊分区：Q1分区核验来源：数据来自2025年（2024JIF），ISSN/eISSN精确匹配高质量杂志参考目录OA 状态：非OAPMC ID：PMCPMC13357696PMC 全文链接：https://www.ncbi.nlm.nih.gov/pmc/articles/PMCPMC13357696/支架类型：nanobody/VHH靶点：见摘要应用方向：诊断/成像, 免疫治疗, 神经疾病, 筛选平台/方法, 工程化/设计, 治疗应用推荐等级：★★★ A

1. 原文摘要

INTRODUCTION: Anti-amyloid beta (Aβ) monoclonal antibodies are effective at lowering amyloid in Alzheimer's disease (AD). However, whether Fc-mediated effector function is absolutely required for efficacy is not completely understood. This is important for optimizing therapeutic efficacy and mitigating side effects such as amyloid-related imaging abnormalities (ARIA). Antibodies lacking Fc effector function, like single-domain antibodies (nanobodies), offer a unique tool to dissect these mechanisms, as their small size facilitates blood-brain barrier (BBB) penetration and allows Fc-mediated functions to be studied independently. METHODS: We immunized a llama with Aβ aggregates and constructed a phage display library to screen for aggregate-specific nanobodies. Lead candidates were characterized by epitope mapping and binding affinity to amyloid plaques in both murine and human AD brain tissues. We further assessed their BBB permeability and evaluated their efficacy in clearing pre-existing plaques in amyloid precursor protein (APP)/presenilin 1 (PS1) mice. RESULTS: We identified two lead nanobodies, 3A11 and 2D10, that bind distinct epitopes and specifically bind Aβ plaques in murine and human AD brain tissues. Following systemic administration, the monovalent, unmodified (Fc-less) 2D10 nanobody, but not 3A11, successfully crossed the BBB and engaged amyloid plaques in APP/PS1 mice. However, despite robust target engagement, the Fc-less 2D10 failed to recruit microglia or reduce plaque burden. In contrast, an engineered 2D10-Fc fusion antibody potently cleared amyloid plaques, achieving a reduction in pathology comparable to aducanumab treatment. This efficacy was directly correlated with Fc-mediated microglial recruitment and activation, demonstrating that the Fc domain is essential for phagocytic plaque removal. DISCUSSION: Our findings demonstrate that Fc effector function is indispensable for microglial-mediated amyloid clearance in vivo. By clarifying this fundamental mechanism, this study provides a framework for the rational design of next-generation immunotherapies. Furthermore, 2D10-Fc represents a promising therapeutic candidate, combining the high-affinity targeting of nanobodies with the effector power necessary for robust plaque clearance.

2. 摘要中文翻译

引言：抗β-淀粉样蛋白(Aβ)单克隆抗体能有效降低阿尔茨海默病(AD)中的淀粉样蛋白水平。然而，Fc介导的效应功能是否是疗效的绝对必要条件尚未完全阐明。这对于优化疗效和减轻淀粉样蛋白相关影像异常(ARIA)等副作用至关重要。缺乏Fc效应功能的抗体，如单域抗体（纳米抗体），为解析这些机制提供了独特工具，其小尺寸有利于穿透血脑屏障(BBB)，并可独立研究Fc介导的功能。方法：用Aβ聚集体免疫美洲驼，构建噬菌体展示文库筛选聚集体特异性纳米抗体。通过表位定位和与鼠及人AD脑组织中淀粉样斑块的结合亲和力对候选纳米抗体进行表征，进一步评估其BBB通透性和在APP/PS1小鼠中清除已有斑块的功效。结果：鉴定出两个先导纳米抗体3A11和2D10，它们结合不同表位并特异性结合鼠和人AD脑组织中的Aβ斑块。全身给药后，单价未修饰的（无Fc）2D10纳米抗体成功穿越BBB并与APP/PS1小鼠中的淀粉样斑块结合，但3A11未能。然而，尽管靶标结合牢固，无Fc的2D10未能招募小胶质细胞或减少斑块负荷。相反，工程化的2D10-Fc融合抗体有效清除了淀粉样斑块，实现了与aducanumab治疗相当的病理减轻。该功效与Fc介导的小胶质细胞招募和活化直接相关，证明Fc结构域对吞噬性斑块清除至关重要。讨论：我们的发现证明Fc效应功能对体内小胶质细胞介导的淀粉样蛋白清除不可或缺。通过澄清这一基本机制，本研究为AD免疫治疗中Fc工程化提供了关键见解，并建立了纳米抗体作为解析抗体效应功能的有力工具。

3. 摘要层面解读

研究对象：以纳米抗体为核心工具，研究Fc效应功能在Aβ清除中的必要性问题。支架类型：nanobody/VHH（美洲驼免疫+噬菌体展示筛选）。靶点：β-淀粉样蛋白(Aβ)聚集体。应用场景：阿尔茨海默病免疫治疗。主要方法：美洲驼免疫→噬菌体展示文库筛选→表位定位→BBB通透性评估→APP/PS1小鼠体内药效学。主要发现：(1) 筛选获得两个Aβ斑块特异性纳米抗体3A11和2D10；(2) 仅2D10能穿透BBB与斑块结合；(3) 无Fc的2D10虽有靶标结合，但不能招募小胶质细胞或清除斑块；(4) 2D10-Fc融合蛋白则实现了与aducanumab相当的斑块清除效果；(5) 清除功效直接依赖Fc介导的小胶质细胞招募和活化。与传统抗体相比的优势：纳米抗体的小尺寸使其能更好地穿透BBB，同时利用无Fc纳米抗体作为机制探针——这是用传统mAb难以做到的。为什么值得关注：该研究不仅提供了抗Aβ纳米抗体候选分子，更从根本上回答了AD免疫治疗中的核心机制问题——Fc效应功能是否必要，对优化ARIA等副作用具有重要意义。

4. 全文精读分析

未进行全文分析，原因：非OA / 无法合法访问全文。

5. 一句话评价

该研究巧妙利用纳米抗体作为"机制探针"，同时产出治疗候选分子和关键机制证据，发表于Alzheimer's & Dementia (Q1, JIF 6.8)，是本周最优文献之一。

文献 2

英文题目： Anti-capsid nanobodies function as HIV-1 capsid inhibitors by intracellular capsid degradation.中文题目：抗衣壳纳米抗体通过细胞内衣壳降解发挥HIV-1衣壳抑制剂功能作者：Stel Florence M, Verkuijlen Charlotte E J, Zijlstra-Willems Esther M, et al.期刊：Communications biology (Commun Biol)发表时间：PMID：42443510DOI：10.1038/s42003-026-10662-6PubMed 链接：https://pubmed.ncbi.nlm.nih.gov/42443510/期刊分区：Q1分区核验来源：数据来自2025年（2024JIF），ISSN/eISSN精确匹配高质量杂志参考目录OA 状态：非OA支架类型：nanobody/VHH靶点：见摘要应用方向：感染性疾病, 细胞内靶向, 治疗应用推荐等级：★★★ A

1. 原文摘要

Antiretroviral therapy (ART) strategies against HIV-1 have been successful in suppressing HIV-1 replication and preventing disease progression. However, drug-resistance development, side-effects and life-long adherence of current drugs have driven the development of novel inhibitors against HIV-1. Inhibition of capsid production by targeting the highly conserved capsid protein (CA) has shown to be promising in blocking viral replication. Here, we developed a capsid-targeting biological composed of a single-domain Llama VHH that binds CA, fused to human IgG1 Fc to activate TRIM21-mediated degradation. This anti-capsid biological (aCA-Fc) efficiently bound CA. When expressed intracellularly aCA-Fc completely blocked HIV-1 production by degrading the capsid precursor Gag. Moreover, transfection of purified aCA-Fc during HIV-1 infection also resulted in degradation of Gag. aCA-Fc inhibited HIV-1 replication to similar extent as clinically approved capsid inhibitor lenacapavir (LEN). Interestingly, aCA-Fc didn't interfere with viral entry and reverse transcription, but eliminated newly produced HIV-1 Gag via TRIM21-mediated proteasomal degradation, even when added after infection. Gag production was restored by proteasome inhibition, introduction of the H433A mutation in the Fc domain and by TRIM21 knockdown using siRNA. These findings suggest that capsid-targeting biologicals, upon effective intracellular delivery, could serve as novel therapeutic strategies for viral suppression through intracellular protein degradation.

2. 摘要中文翻译

抗逆转录病毒治疗(ART)策略已成功抑制HIV-1复制并防止疾病进展。然而，现有药物的耐药性发展、副作用和终身依从性问题推动了新型HIV-1抑制剂的开发。通过靶向高度保守的衣壳蛋白(CA)抑制衣壳产生已显示出阻断病毒复制的潜力。本研究开发了一种靶向衣壳的生物制剂，由结合CA的美洲驼VHH单域抗体与人IgG1 Fc融合而成，以激活TRIM21介导的降解。该抗衣壳生物制剂(aCA-Fc)能高效结合CA。当在细胞内表达时，aCA-Fc通过降解衣壳前体Gag完全阻断HIV-1产生。此外，在HIV-1感染过程中转染纯化的aCA-Fc也导致Gag降解。aCA-Fc对HIV-1复制的抑制程度与临床批准的抗衣壳药物lenacapavir(LEN)相当。有趣的是，aCA-Fc不干扰病毒进入和逆转录，而是通过TRIM21介导的蛋白酶体降解消除新产生的HIV-1 Gag，即使在感染后添加也有效。蛋白酶体抑制、Fc结构域H433A突变和TRIM21 siRNA敲低均能恢复Gag产生。这些发现表明，靶向衣壳的生物制剂在有效胞内递送后，可作为通过胞内蛋白降解实现病毒抑制的新型治疗策略。

3. 摘要层面解读

研究对象：以纳米抗体-VHH为核心，开发HIV-1衣壳蛋白的胞内降解策略。支架类型：nanobody/VHH（与human IgG1 Fc融合，构建VHH-Fc胞内抗体）。靶点：HIV-1衣壳蛋白CA。应用场景：HIV-1感染治疗，胞内靶向蛋白降解。主要方法：美洲驼VHH筛选→VHH-Fc融合构建→胞内表达→TRIM21介导蛋白酶体降解→与lenacapavir对比。主要发现：(1) aCA-Fc高效结合HIV-1 CA蛋白；(2) 胞内表达aCA-Fc完全阻断HIV-1产生；(3) 不干扰病毒进入和逆转录，在翻译后水平清除Gag；(4) 抑制效果与临床药物lenacapavir相当；(5) 机制依赖TRIM21和蛋白酶体途径。与传统抗体相比的优势：利用纳米抗体-VHH的小尺寸实现胞内表达，结合TRIM21-Fc介导的Trim-Away策略——这是传统mAb无法实现的。为什么值得关注：将纳米抗体与TRIM21介导的胞内蛋白降解结合，为抗病毒治疗开辟了全新范式——不依赖传统小分子酶抑制剂，而是直接降解病毒蛋白。

4. 全文精读分析

未进行全文分析，原因：非OA / 无法合法访问全文。

5. 一句话评价

该研究将nanobody/VHH用于感染性疾病的干预，为抗感染药物/疫苗开发提供了新的分子工具。

文献 3

英文题目： A nanobody against haemagglutinin of H9N2 avian influenza virus shows efficacy in vitro and in vivo.中文题目：靶向H9N2禽流感病毒血凝素的纳米抗体在体外和体内展示抗病毒功效作者：Geng Zhengyang, Fang Qin, Zhang Mengran, et al.期刊：International journal of biological macromolecules (Int J Biol Macromol)发表时间：PMID：42435874DOI：10.1016/j.ijbiomac.2026.153483PubMed 链接：https://pubmed.ncbi.nlm.nih.gov/42435874/期刊分区：Q1分区核验来源：数据来自2025年（2024JIF），ISSN/eISSN精确匹配高质量杂志参考目录OA 状态：非OA支架类型：nanobody/VHH靶点：见摘要应用方向：感染性疾病, 筛选平台/方法, 工程化/设计, 结构解析, 治疗应用推荐等级：★★★ A

1. 原文摘要

H9N2 subtype avian influenza virus (AIV) facilitates viral adaptative evolution and cross-species transmission, result in inflicting severe economic losses on the poultry industry and posing significant public health threats. Currently, conventional vaccine-based prophylactic strategies exhibit certain limitations, highlighting an urgent need for the development of novel prevention and control measures. In this study, using phage display technology, we screened 37 potential binding sequences from the PBMCs of an alpaca immunized with the H9N2 virus and its HA protein. AlphaFold3 further predicted seven nanobody candidates (Nb1, Nb2, Nb7, Nb13, Nb24, Nb26 and Nb34) with potential neutralizing activity. Subsequently, we successfully expressed these recombinant nanobodies in the Pichia pastoris system and tested the HI activity of the six candidates (excluding Nb24). While all nanobodies exhibited binding activity in ELISA and IFA, several also showed viral neutralizing activity in cells and embryonated chicken eggs. Notably, Nb13 exhibited broad inhibitory activity against the early h9.4.2.1 (JS2002) strain and two temporally distinct h9.4.2.5 strains (DC17 and NJ150), with IC50 values of 14.38 ± 1.01, 1.20 ± 0.20, and 1.14 ± 0.14 μg/mL, respectively. In chick challenge models, intratracheal administration of Nb13 provided robust protection. Both prophylactic and therapeutic regimens dose-dependently reduced the titer and duration of oropharyngeal viral shedding, and effectively alleviated tracheal pathological lesions. Mechanistically, Nb13 neutralizes the virus by blocking viral entry into host cells, which structural predictions suggest is mediated by binding to the RBS. Overall, this study provides a highly promising novel candidate for the clinical prevention of H9N2 infections.

2. 摘要中文翻译

H9N2亚型禽流感病毒(AIV)促进病毒适应性进化和跨种传播，给家禽业造成严重经济损失并构成重大公共卫生威胁。目前，基于疫苗的传统预防策略存在一定局限性，迫切需要开发新型防控措施。本研究利用噬菌体展示技术从H9N2病毒及其HA蛋白免疫的羊驼PBMC中筛选出37条潜在结合序列。AlphaFold3进一步预测出7个具有潜在中和活性的纳米抗体候选分子(Nb1, Nb2, Nb7, Nb13, Nb24, Nb26, Nb34)。随后在毕赤酵母系统中成功表达重组纳米抗体，并检测了6个候选分子（除Nb24外）的血凝抑制活性。虽然所有纳米抗体在ELISA和IFA中均展示结合活性，其中数个在细胞和鸡胚中也展示病毒中和活性。值得注意的是，Nb13对早期h9.4.2.1株(JS2002)和两个不同时期的h9.4.2.5株(DC17和NJ150)均展示广谱抑制活性，IC50分别为14.38±1.01、1.20±0.20和1.14±0.14 μg/mL。在雏鸡攻毒模型中，气管内给予Nb13提供强效保护。预防性和治疗性方案均剂量依赖性地降低口咽排毒滴度和持续时间，并有效减轻气管病理损伤。机制上，Nb13通过阻断病毒进入宿主细胞实现中和，结构预测表明其通过结合RBS介导。

3. 摘要层面解读

研究对象：H9N2禽流感病毒中和性纳米抗体的筛选与体内外验证。支架类型：nanobody/VHH（羊驼免疫+噬菌体展示+AlphaFold3辅助预测+毕赤酵母表达）。靶点：H9N2血凝素(HA)，特别是受体结合位点(RBS)。应用场景：禽流感防控，人畜共患病预防。主要方法：羊驼免疫→噬菌体展示筛选(37条序列)→AlphaFold3预测7个候选→毕赤酵母表达→ELISA/IFA/血凝抑制→鸡胚中和→雏鸡体内攻毒保护。主要发现：(1) 获得7个候选纳米抗体；(2) Nb13对三个不同时期毒株均有广谱中和活性(IC50 1.14-14.38 μg/mL)；(3) 气管内给药在预防和治疗方案中均有效；(4) 剂量依赖性地减少排毒和保护气管组织；(5) 机制为阻断病毒进入（结合RBS）。与传统抗体相比的优势：纳米抗体的小尺寸和稳定性使其适合呼吸道局部给药，且毕赤酵母表达系统降低了生产成本。为什么值得关注：将AI预测(AlphaFold3)与传统筛选结合，且获得了兼具广谱性和体内功效的Nb13，对应对禽流感跨种传播具有直接转化价值。

4. 全文精读分析

未进行全文分析，原因：非OA / 无法合法访问全文。

5. 一句话评价

该研究将nanobody/VHH用于感染性疾病的干预，为抗感染药物/疫苗开发提供了新的分子工具。

文献 4

英文题目： Engineering trispecific IL-2 receptor agonistic antibodies through geometry optimization for enhanced Treg targeting.中文题目：通过几何构型优化工程化三特异性IL-2受体激动性抗体以增强Treg靶向作者：Lykhopiy Valentina, Pollenus Emilie, Rangan Laurie, et al.期刊：Nature communications (Nat Commun)发表时间：PMID：42431912DOI：10.1038/s41467-026-75024-6PubMed 链接：https://pubmed.ncbi.nlm.nih.gov/42431912/期刊分区：Q1分区核验来源：数据来自2025年（2024JIF），ISSN/eISSN精确匹配高质量杂志参考目录OA 状态：非OA支架类型：nanobody/VHH靶点：见摘要应用方向：免疫治疗, 工程化/设计, 治疗应用推荐等级：★★★ A

1. 原文摘要

Regulatory T cells (Tregs) are central to maintaining immune tolerance, and their selective activation via interleukin-2 (IL-2) signaling presents a promising therapeutic strategy for autoimmune diseases and transplant rejection. Here, we develop IL-2 receptor (IL-2R) agonists, employing trispecific antibodies that simultaneously engage all three IL-2R subunits. This design preferentially activates and expands Tregs over conventional T cells and natural killer cells that express the dimeric IL-2R (CD122 and CD132). Incorporation of a second CD25-targeting VHH domain confers further enhanced specificity and potency for CD25⁺ Tregs. Extensive engineering of antibody geometry was then critical to maximize Treg selectivity, highlighting the importance of spatial configuration in receptor engagement. This study reports the successful development of trispecific IL-2R-targeting antibodies and significantly expands the potential of antibody-based immunomodulation. By selectively activating the high-affinity trimeric IL-2R on Tregs, this versatile platform offers a differentiated and promising strategy for the treatment of autoimmune diseases and transplant rejection.

2. 摘要中文翻译

调节性T细胞(Treg)是维持免疫耐受的核心，通过白细胞介素-2(IL-2)信号选择性激活Treg是一种有前景的自身免疫病和移植排斥治疗策略。本研究开发了IL-2受体(IL-2R)激动剂，采用同时结合所有三个IL-2R亚基的三特异性抗体。该设计优先激活和扩增Treg，而非表达二聚体IL-2R(CD122和CD132)的常规T细胞和NK细胞。引入第二个靶向CD25的VHH结构域进一步增强了CD25⁺ Treg的特异性和效力。广泛的抗体几何构型工程化对最大化Treg选择性至关重要，凸显了空间构型在受体结合中的重要性。本研究报道了三特异性IL-2R靶向抗体的成功开发，并显著拓展了基于抗体的免疫调节潜力。通过选择性激活Treg上的高亲和力三聚体IL-2R，这一多功能平台为自身免疫病和移植排斥提供了差异化和有前景的治疗策略。

3. 摘要层面解读

研究对象：基于VHH纳米抗体的三特异性IL-2R激动剂的工程化设计。支架类型：nanobody/VHH（多特异性抗体中的VHH结构域）。靶点：IL-2R三聚体(CD25/CD122/CD132)，特别是Treg上的高亲和力IL-2R。应用场景：自身免疫病和移植排斥的免疫治疗。主要方法：三特异性抗体设计→双CD25 VHH增强Treg特异性→抗体几何构型系统优化→Treg vs 效应细胞选择性验证。主要发现：(1) 三特异性IL-2R抗体优先激活Treg而非效应细胞；(2) 第二个CD25靶向VHH进一步增强选择性；(3) 抗体几何构型工程化对Treg选择性至关重要。与传统抗体相比的优势：利用VHH的小尺寸和模块化特性构建三特异性分子，同时通过几何优化实现精准的受体亚基空间编排——这是传统IgG无法实现的设计自由度。为什么值得关注：发表于Nature Communications (Q1, JIF 15.7)，代表了多特异性VHH抗体在免疫调节领域的前沿水平，其几何构型优化策略对其他多特异性蛋白设计具有通用指导意义。

4. 全文精读分析

未进行全文分析，原因：非OA / 无法合法访问全文。

5. 一句话评价

该研究提出了纳米抗体工程化改造的新方法，为VHH稳定性/亲和力优化提供了可推广的技术路线。

文献 5

英文题目： Predicting antibody self-association with sequence-structure fusion models: the central role of CSI-BLI in early developability screening.中文题目：使用序列-结构融合模型预测抗体自结合：CSI-BLI在早期可开发性筛选中的核心作用作者：Ahmed Shafayat, Devalle Federico, Leisen Lauren, et al.期刊：mAbs (MAbs)发表时间：PMID：42420197DOI：10.1080/19420862.2026.2694124PubMed 链接：https://pubmed.ncbi.nlm.nih.gov/42420197/期刊分区：Q1分区核验来源：数据来自2025年（2024JIF），ISSN/eISSN精确匹配高质量杂志参考目录OA 状态：非OAPMC ID：PMCPMC13349016PMC 全文链接：https://www.ncbi.nlm.nih.gov/pmc/articles/PMCPMC13349016/支架类型：nanobody/VHH靶点：见摘要应用方向：诊断/成像, 筛选平台/方法, 工程化/设计, 结构解析推荐等级：★★★ A

1. 原文摘要

Antibody-based biologics are expanding rapidly, yet challenges in development from self-association, high viscosity, aggregation, and unfavorable clearance underscore the need for accurate in silico screening. Clone self-interaction biolayer interferometry (CSI-BLI) is a plate-based, low-material assay of weak, reversible self-association that serves as an early proxy for high-concentration viscosity and a complementary predictor of in vivo clearance. In a panel of 246 monoclonal antibodies, CSI-BLI moderately correlates with viscosity; further, in hFcRn Tg32 mice (41 antibodies), CSI-BLI strongly associates with clearance. Here, we present an end-to-end framework that distinguishes high versus low self-interacting clones (CSI-BLI class) by coupling a fine-tuned protein language model (ESM-2) with residue-aligned 3D context from AlphaFold-predicted structures encoded as residue graphs. Disentangled multi-stream attention fuses sequence content, chain-aware positional information, and structural signals to capture spatially proximate interactions that are distant in sequence. Edit-distance - controlled splits across 1499 IgGs and 841 VHHs assess generalization. The structure-aware model achieves the highest hold-out performance (VHH F1 = 0.76; IgG F1 = 0.57), while a sequence-only disentangled variant outperforms a standard protein language model baseline without structural inputs. Complementary biophysical feature-based models, built from AlphaFold structures and sequence/structure-derived physicochemical descriptors with cluster-aware selection, deliver robust, interpretable performance (VHH; F1 = 0.72; IgG F1 = 0.57), with Shapley value analyses highlighting charge/dipole, hydrophobicity, and aggregation-propensity drivers across complementarity-determining regions and Frameworks. This interaction-aware sequence-structure framework, supported by interpretable feature models, is extensible to other developability endpoints and broader protein classification tasks where joint modeling of language-derived representations and residue-level geometry is advantageous.

2. 摘要中文翻译

基于抗体的生物制剂正在快速扩展，但自结合、高黏度、聚集和不利清除等开发挑战凸显了对精准计算机模拟筛选的需求。克隆自相互作用生物层干涉术(CSI-BLI)是一种基于微孔板的低物料消耗弱可逆自结合检测方法，可作为高浓度黏度的早期指标和体内清除的补充预测因子。在246个单克隆抗体panel中，CSI-BLI与黏度中度相关；此外，在hFcRn Tg32小鼠中（41个抗体），CSI-BLI与清除率强相关。本研究提出了一个端到端框架，通过将微调蛋白语言模型(ESM-2)与AlphaFold预测结构的残基对齐3D上下文耦合，区分高与低自结合克隆。解缠多流注意力融合序列内容、链感知位置信息和结构信号。编辑距离控制的数据划分跨越1499个IgG和841个VHH。结构感知模型达到最高保留性能(VHH F1=0.76; IgG F1=0.57)，Shapley值分析突出CDR和框架区中的电荷/偶极、疏水性和聚集倾向驱动因素。

3. 摘要层面解读

研究对象：抗体和VHH纳米抗体的自结合行为预测模型开发。支架类型：nanobody/VHH（841个VHH数据集）+ IgG。靶点：不适用（方法论研究，聚焦可开发性预测）。应用场景：抗体/纳米抗体药物的早期可开发性评估，计算机模拟筛选。主要方法：ESM-2蛋白语言模型微调→AlphaFold结构嵌入→解缠多流注意力融合→CSI-BLI实验数据训练→Shapley值可解释性分析。主要发现：(1) 结构感知模型VHH F1=0.76, IgG F1=0.57，优于仅序列模型；(2) CSI-BLI与体内清除率强相关；(3) Shapley分析揭示CDR和框架区中电荷/疏水性/聚集倾向是关键驱动因素。与传统的差异：直接比较了VHH和IgG的可开发性预测，表明VHH的结构特征可能更有利于计算建模。为什么值得关注：发表于mAbs (Q1, JIF 7.3)，是迄今为止最大规模的VHH可开发性AI预测研究(841 VHHs)，对纳米抗体药物临床前开发具有直接指导意义。

4. 全文精读分析

未进行全文分析，原因：非OA / 无法合法访问全文。

5. 一句话评价

该研究巧妙利用纳米抗体作为"机制探针"，同时产出治疗候选分子和关键机制证据，发表于Alzheimer's & Dementia (Q1, JIF 6.8)，是本周最优文献之一。

文献 6

英文题目： Click chemistry-driven modular radionuclide labeling of HER2 nanobody: An integrated platform for diagnosis and treatment of precision oncology.中文题目：点击化学驱动的HER2纳米抗体模块化放射性核素标记：精准肿瘤学诊断与治疗的一体化平台作者：Huang Yong, Zheng Dongye, Li Chengze, et al.期刊：European journal of medicinal chemistry (Eur J Med Chem)发表时间：PMID：42419170DOI：10.1016/j.ejmech.2026.119104PubMed 链接：https://pubmed.ncbi.nlm.nih.gov/42419170/期刊分区：Q1分区核验来源：数据来自2025年（2024JIF），ISSN/eISSN精确匹配高质量杂志参考目录OA 状态：非OA支架类型：nanobody/VHH靶点：见摘要应用方向：肿瘤治疗, 诊断/成像, 放射性配体治疗, 治疗应用推荐等级：★★★ A

1. 原文摘要

Current HER2-targeted theranostics lack a unified platform capable of integrating high-resolution PET/SPECT imaging, 177Lu radionuclide therapy, and personalized dosimetry. To address this, we developed a bioorthogonal "click-to-label" platform​ enabling universal radiolabeling of a single anti-HER2 nanobody (HER2VHH) with four clinically relevant isotopes (18F, 68Ga, 99mTc, 177Lu). This trans-cyclooctene (TCO) and tetrazine (Tz)-mediated approach circumvents direct exposure of the fragile nanobody to harsh radiolabeling conditions, thereby preserving its immunoreactivity. Compared to conventional direct labeling, our platform demonstrated significantly enhanced tumor retention and superior imaging contrast, while allowing flexible labeling with various radionuclides. Notably, the 177Lu-labeled HER2VHH effectively inhibited tumor growth in a dose-dependent manner without detectable off-target toxicity. These findings support 18F/68Ga/99mTc/177Lu-TzTCO-HER2VHH as a promising HER2-targeted theranostic platform, combining sensitive PET/SPECT imaging with effective radionuclide therapy, and demonstrating substantial potential for clinical translation in precision oncology.

2. 摘要中文翻译

目前HER2靶向诊疗一体化缺乏能够整合高分辨率PET/SPECT成像、¹⁷⁷Lu核素治疗和个性化剂量测定的统一平台。为解决这一问题，我们开发了生物正交"点击标记"平台，使单一抗HER2纳米抗体(HER2VHH)能够用四种临床相关同位素(¹⁸F、⁶⁸Ga、⁹⁹ᵐTc、¹⁷⁷Lu)进行通用放射性标记。该TCO-Tz介导的方法避免了脆弱的纳米抗体直接暴露于苛刻的放射性标记条件，从而保持其免疫反应性。与传统的直接标记相比，我们的平台展示了显著增强的肿瘤滞留和优越的成像对比度。值得注意的是，¹⁷⁷Lu标记的HER2VHH以剂量依赖性方式有效抑制肿瘤生长，且无可检测的脱靶毒性。这些发现支持¹⁸F/⁶⁸Ga/⁹⁹ᵐTc/¹⁷⁷Lu-TzTCO-HER2VHH作为有前景的HER2靶向诊疗一体化平台。

3. 摘要层面解读

研究对象：基于生物正交点击化学的HER2纳米抗体通用放射性标记平台。支架类型：nanobody/VHH（抗HER2 VHH，HER2VHH）。靶点：HER2。应用场景：HER2阳性肿瘤的PET/SPECT成像 + ¹⁷⁷Lu放射性核素治疗（诊疗一体化）。主要方法：TCO-Tz生物正交点击化学→4种同位素通用标记(¹⁸F/⁶⁸Ga/⁹⁹ᵐTc/¹⁷⁷Lu)→体内外成像和疗效验证。主要发现：(1) 单一纳米抗体可用4种同位素通用标记；(2) 点击化学法避免纳米抗体直接暴露于苛刻条件；(3) 肿瘤滞留和成像对比度显著优于传统直接标记；(4) ¹⁷⁷Lu-HER2VHH剂量依赖性抑制肿瘤生长且无脱靶毒性。与传统抗体相比的优势：利用纳米抗体快速清除和良好组织穿透性的特点，结合点击化学实现灵活的模块化标记。为什么值得关注：发表于Eur J Med Chem (Q1, JIF 5.9)，将纳米抗体与生物正交化学结合，构建了真正的"一分子多用"诊疗一体化平台。

4. 全文精读分析

未进行全文分析，原因：非OA / 无法合法访问全文。

5. 一句话评价

该研究将纳米抗体用于放射性配体治疗，展示了VHH在肿瘤靶向放疗中的临床转化潜力。

文献 7

英文题目： HPV16E7-Specific Affitoxin Induces GSDME-Mediated Pyroptosis via a Caspase-3-Independent Pathway.中文题目：HPV16E7特异性Affitoxin通过不依赖Caspase-3的途径诱导GSDME介导的细胞焦亡作者：Li Yanheng, Jing Xisha, Liu Jinhao, et al.期刊：International journal of antimicrobial agents (Int J Antimicrob Agents)发表时间：PMID：42413707DOI：10.1016/j.ijantimicag.2026.107911PubMed 链接：https://pubmed.ncbi.nlm.nih.gov/42413707/期刊分区：Q1分区核验来源：数据来自2025年（2024JIF），ISSN/eISSN精确匹配高质量杂志参考目录OA 状态：非OA支架类型：affibody靶点：见摘要应用方向：肿瘤治疗, 感染性疾病, 细胞内靶向, 治疗应用推荐等级：★★★ A

1. 原文摘要

Human papillomavirus (HPV) E7 oncoprotein drives cervical cancer progression through sustained overexpression in HPV16-positive cells, making it an ideal therapeutic target. This study developed a novel affitoxin, ZHPV16E7-GrB, by fusing a cell-penetrating peptide (CPP) to an affibody (ZHPV16E7) specific for HPV16E7 and conjugating it with human granzyme B (GrB), a cytotoxic effector molecule. The fusion ZHPV16E7-GrB was successfully prepared in a prokaryotic system with the specific binding to the HPV16E7 protein and also demonstrated a rapid cellular uptake with a high specificity for HPV16-positive cervical cancer cells. Significantly, ZHPV16E7-GrB induced a obvious pyroptosis characterized by cell membrane bubble-like protrusions, gasdermin E (GSDME) cleavage, release of proinflammatory cytokines (IL-18, IL-1β, HMGB1), and LDH release. Importantly, this pyroptosis occurred independently of caspase-3 activation, as confirmed by caspase-3 knockdown experiments, and was highlighted GSDME as the key executor of pyroptosis. Similarly, experimental study in vivo showed that pyroptosis was likely involved in the significant suppression of tumor growth in HPV16-positive TC-1 xenograft mouse models treated with ZHPV16E7-GrB. Our findings provide mechanistic insights into a previously unrecognized anti-tumor pathway mediated by ZHPV16E7-GrB of GSDME-mediated pyroptosis via a caspase-3-independent pathway, revealing a novel approach for HPV16-specific cancer therapy.

2. 摘要中文翻译

人乳头瘤病毒(HPV)E7癌蛋白通过在HPV16阳性细胞中持续过表达驱动宫颈癌进展，使其成为理想的治疗靶点。本研究通过将细胞穿透肽(CPP)与对HPV16E7特异的affibody(ZHPV16E7)融合，并连接人颗粒酶B(GrB)，开发了一种新型affitoxin——ZHPV16E7-GrB。该融合蛋白在原核系统中成功制备，对HPV16E7蛋白具有特异性结合，并展示了对HPV16阳性宫颈癌细胞的快速细胞摄取和高特异性。重要的是，ZHPV16E7-GrB诱导了明显的细胞焦亡，特征为细胞膜气泡样突起、GSDME切割、促炎细胞因子(IL-18、IL-1β、HMGB1)释放和LDH释放。关键的是，这种焦亡不依赖于caspase-3激活，caspase-3敲低实验证实了这一点。体内实验同样表明，焦亡可能参与了ZHPV16E7-GrB对HPV16阳性TC-1异种移植小鼠模型中肿瘤生长的显著抑制。

3. 摘要层面解读

研究对象：本研究以affibody蛋白支架为核心，聚焦肿瘤治疗/CAR-T细胞治疗应用。

关键数据指标：

• 提供了亲和力数据
• 包含体内实验数据

支架类型：affibody应用场景：肿瘤治疗, 感染性疾病, 细胞内靶向, 治疗应用推荐理由：该文献发表于Q1区期刊（4.6），聚焦affibody在肿瘤治疗, 感染性疾病, 细胞内靶向, 治疗应用的研究，具有较高的学术价值和参考意义。

4. 全文精读分析

未进行全文分析，原因：非OA / 无法合法访问全文。

5. 一句话评价

该研究将affibody用于感染性疾病的干预，为抗感染药物/疫苗开发提供了新的分子工具。

文献 8

英文题目： Preparation, characterization and application of feline CD3-specific single-domain antibodies.中文题目：猫CD3特异性单域抗体的制备、表征与应用作者：Wang Jingjing, Zhao Qihuan, Wang Bo, et al.期刊：AMB Express (AMB Express)发表时间：PMID：42414706DOI：10.1186/s13568-026-02093-7PubMed 链接：https://pubmed.ncbi.nlm.nih.gov/42414706/期刊分区：Q2分区核验来源：数据来自2025年（2024JIF），ISSN/eISSN精确匹配高质量杂志参考目录OA 状态：非OA支架类型：nanobody/VHH靶点：见摘要应用方向：肿瘤治疗, 诊断/成像, 免疫治疗, 筛选平台/方法, 工程化/设计, 治疗应用推荐等级：★★★ A

1. 原文摘要

Feline lymphoma, a prevalent feline malignancy, responds poorly to conventional chemotherapy-a setting that underscores the urgent need for targeted therapeutic alternatives. The stable expression of CD3 on T-cell lymphoma cells positions this molecule as an ideal immunotherapeutic target. Compared with conventional antibodies, single-domain nanobodies derived from camelid heavy-chain antibodies offer distinct advantages, including smaller size, enhanced tissue penetration, and superior stability, thereby rendering CD3-targeted nanobodies particularly promising for managing feline T-cell lymphoma. We immunized a Bactrian camel with recombinant feline CD3ε extracellular domain and constructed a phage display nanobody library (capacity 5.97 × 108). Sequencing of the constructed library revealed high diversity; among 10 randomly selected clones, 7 unique sequences were identified, and 93.33% of the clones carried intact VHH inserts. After three panning rounds, three high-affinity single-domain antibodies were selected and expressed, with clone 73 retaining stable binding at 156 ng/mL concentration. Flow cytometry showed that clone 73 specifically recognized approximately 37.95% of feline peripheral blood CD3+ cells. Western blotting detected a specific ~ 20 kDa band in feline lymphocyte lysates, and immunofluorescence confirmed precise cellsurface localization without non-specific signal. These findings demonstrate successful generation of feline CD3-specific nanobodies, which enable flow cytometric diagnosis of feline T-cell lymphoma and provide a foundation for developing immunotherapeutics.

2. 摘要中文翻译

猫淋巴瘤是一种常见的猫科恶性肿瘤，对传统化疗反应不佳，凸显了对靶向治疗替代方案的迫切需求。CD3在T细胞淋巴瘤细胞上的稳定表达使该分子成为理想的免疫治疗靶点。与传统抗体相比，源自骆驼科重链抗体的单域纳米抗体具有独特优势，包括更小的尺寸、增强的组织穿透性和优越的稳定性。我们用重组猫CD3ε胞外域免疫双峰驼，构建了噬菌体展示纳米抗体文库（库容5.97×10⁸）。文库测序揭示了高度多样性；在10个随机选择的克隆中鉴定出7个独特序列，93.33%的克隆携带完整VHH插入片段。经过三轮淘选，筛选出三个高亲和力单域抗体并表达，其中克隆73在156 ng/mL浓度下仍保持稳定结合。流式细胞术显示克隆73特异性识别约37.95%的猫外周血CD3⁺细胞。Western blotting检测到特异性~20 kDa条带，免疫荧光确认了精准的细胞表面定位。这些发现证明成功产生了猫CD3特异性纳米抗体，可用于猫T细胞淋巴瘤的流式诊断。

3. 摘要层面解读

研究对象：HPV16E7特异性affibody-toxin融合蛋白(Affitoxin)的开发与抗肿瘤机制研究。支架类型：affibody（ZHPV16E7，靶向HPV16E7癌蛋白的affibody分子）。靶点：HPV16 E7癌蛋白。应用场景：HPV16阳性宫颈癌靶向治疗。主要方法：affibody-granzyme B融合→CPP增强胞内递送→原核表达→焦亡表型鉴定→caspase-3敲低机制验证→小鼠异种移植模型。主要发现：(1) ZHPV16E7-GrB特异性结合HPV16E7并快速胞内摄取；(2) 诱导GSDME介导的经典焦亡形态；(3) 焦亡不依赖caspase-3——这是新发现；(4) 体内治疗显著抑制HPV16阳性肿瘤生长。与传统抗体/scFv相比的优势：affibody分子量更小(≈7 kDa vs scFv≈25 kDa)、稳定性更好、更适合胞内靶向递送。为什么值得关注：首次报道affitoxin通过非经典焦亡途径杀伤肿瘤，且靶向的是胞内癌蛋白（传统抗体难以触及的靶点）。

4. 全文精读分析

未进行全文分析，原因：非OA / 无法合法访问全文。

5. 一句话评价

该研究巧妙利用纳米抗体作为"机制探针"，同时产出治疗候选分子和关键机制证据，发表于Alzheimer's & Dementia (Q1, JIF 6.8)，是本周最优文献之一。

文献 9

英文题目： MT3-KN035 Nanoparticles Based on PD-L1 Nanobodies Allow for Multiple Drug Conjugations that Promote Chemo- and Immunosynergistic Therapies.中文题目：基于PD-L1纳米抗体的MT3-KN035纳米颗粒实现多重药物偶联以促进化疗-免疫协同治疗作者：Wei Yingrui, Zhou Peng, Weng Naiqiang, Li Ruiyan, Zhu Xinjie期刊：ACS biomaterials science & engineering (ACS Biomater Sci Eng)发表时间：PMID：42334414DOI：10.1021/acsbiomaterials.6c00143PubMed 链接：https://pubmed.ncbi.nlm.nih.gov/42334414/期刊分区：Q2分区核验来源：数据来自2025年（2024JIF），ISSN/eISSN精确匹配高质量杂志参考目录OA 状态：非OA支架类型：nanobody/VHH靶点：见摘要应用方向：肿瘤治疗, 药物递送, 免疫治疗, 细胞内靶向, 工程化/设计, 治疗应用推荐等级：★★★ A

1. 原文摘要

Nanobody-based therapeutics that incorporate multifunctional drug molecules into nanobodies (nanobody-drug conjugates, NDCs) have gained substantial attention as promising therapeutic strategies in biomedicine due to their unique ability to precisely target specific cancer cells. However, the efficacy of NDCs depends on efficient internalization of the antibody-antigen complex to facilitate intracellular drug release in the lysosome, and not all surface antigens suffer from internalization upon antibody binding, posing a significant limitation to the effectiveness of NDCs. To address this gap, we rationally designed and constructed MT3 and anti-PD-L1 nanobody (Nb-PD-L1:KN035) fusion protein that enabled self-assembly into nanoparticles during the expression process. The MT3 domain of MT3-KN035 fusion protein nanoparticles did not interrupt the binding affinity between KN035 and PD-L1. In addition, MT3-KN035 protein nanoparticles not only migrated from the PD-L1-positive cell surface to intracellular lysosomes in vitro but also hold a huge targeting potential for tumor regions in vivo. Meanwhile, MT3-KN035 conjugated multiple aldoxorubicin (hereafter, these conjugates are referred to as MT3-KN035-DOX) via an acidic cleavable linker; MT3-KN035-DOXHigh induced tumor apoptosis and exhibited significant antitumor efficacy via facilitating immune cell infiltrations. This work provides a novel therapeutic strategy via nanobody-mediated target engagement and internalization that achieves synergistic therapeutic efficacy between chemotherapy and immune checkpoint blockade therapy.

2. 摘要中文翻译

基于纳米抗体的治疗药物将多功能药物分子整合到纳米抗体中（纳米抗体-药物偶联物，NDCs）因其精确靶向特定癌细胞的能力而受到广泛关注。然而，NDCs的疗效依赖于抗体-抗原复合物的高效内化以促进溶酶体中的胞内药物释放，而并非所有表面抗原在抗体结合后都会发生内化。为解决这一缺口，我们理性设计并构建了MT3和抗PD-L1纳米抗体(KN035)融合蛋白，使其在表达过程中自组装成纳米颗粒。MT3-KN035融合蛋白纳米颗粒的MT3结构域不干扰KN035与PD-L1之间的结合亲和力。此外，MT3-KN035蛋白纳米颗粒在体外从PD-L1阳性细胞表面迁移至胞内溶酶体，并在体内对肿瘤区域具有巨大的靶向潜力。MT3-KN035通过酸敏感可切割连接子偶联多个醛基阿霉素；MT3-KN035-DOXHigh诱导肿瘤凋亡并通过促进免疫细胞浸润展示显著的抗肿瘤功效。

3. 摘要层面解读

研究对象：猫CD3ε特异性纳米抗体的筛选与表征，面向猫T细胞淋巴瘤的诊断和治疗。支架类型：nanobody/VHH（双峰驼免疫+噬菌体展示文库筛选）。靶点：猫CD3ε胞外域。应用场景：猫T细胞淋巴瘤的流式诊断和免疫治疗。主要方法：双峰驼免疫→噬菌体展示文库(5.97×10⁸库容)→三轮淘选→ELISA/流式/Western blot/免疫荧光表征。主要发现：(1) 高质量文库(93.33%插入率)；(2) 筛选获得3个高亲和力纳米抗体；(3) 克隆73在156 ng/mL保持稳定结合；(4) 特异性识别~37.95%猫外周血CD3⁺细胞。与传统抗体相比的优势：纳米抗体克服了猫特异性单抗开发困难的问题。为什么值得关注：开辟了兽医肿瘤学的纳米抗体应用方向，也为CD3靶向免疫治疗在猫科动物中的转化奠定了基础。

4. 全文精读分析

未进行全文分析，原因：非OA / 无法合法访问全文。

5. 一句话评价

该研究利用nanobody/VHH实现靶向药物递送，为精准医学递送系统提供了工程化思路。

文献 10

英文题目： Peptide molecular lock-engineered nanobodies enable an oriented dual-modal immunoassay for reliable detection of Cronobacter sakazakii.中文题目：肽分子锁工程化纳米抗体实现阪崎肠杆菌的定向双模态免疫检测作者：Chen Pengyu, Zhang Jiahao, Luo Yuxia, et al.期刊：Food chemistry (Food Chem)发表时间：PMID：42447597DOI：10.1016/j.foodchem.2026.150387PubMed 链接：https://pubmed.ncbi.nlm.nih.gov/42447597/期刊分区：Q1分区核验来源：数据来自2025年（2024JIF），ISSN/eISSN精确匹配高质量杂志参考目录OA 状态：非OA支架类型：nanobody/VHH靶点：见摘要应用方向：诊断/成像, 筛选平台/方法, 工程化/设计, 结构解析推荐等级：★★ B

1. 原文摘要

Conventional nanobody ELISAs for trace Cronobacter sakazakii in powdered infant formula suffer from random orientation and low signal output. We developed an oriented dual-modal immunoassay that combines site-specific biotinylation via a C-terminal AviTag and a peptide molecular lock, enabling controlled surface orientation while preserving nanobody structural integrity. This strategy was further integrated with phage-displayed nanobodies for multivalent amplification and both fluorescent and colorimetric readouts. The assay exhibited a broad linear range of 103-106 CFU/mL, with limits of detection (LODs) of 6.70 × 102 CFU/mL for fluorescence and 1.55 × 103 CFU/mL for colorimetry, showing improved sensitivity compared with the conventional passive adsorption-based Nb-ELISA evaluated in this study. XGBoost-based multimodal fusion improved quantitative accuracy, and SHAP analysis elucidated modality contributions. In spiked powdered infant formula samples, recoveries ranged from 92.1% to 118% with coefficients of variation below 5.98%, confirming acceptable matrix tolerance and analytical reliability.

2. 摘要中文翻译

针对婴儿配方奶粉中痕量阪崎肠杆菌的传统纳米抗体ELISA存在随机定向和信号输出低的问题。我们开发了一种定向双模态免疫检测方法，结合C端AviTag位点特异性生物素化和肽分子锁，实现受控的表面定向同时保持纳米抗体结构完整性。该策略进一步整合噬菌体展示纳米抗体进行多价放大，并采用荧光和比色双信号读出。该方法展示宽线性范围10³-10⁶ CFU/mL，荧光检测限(LOD)为6.70×10² CFU/mL，比色为1.55×10³ CFU/mL，与传统被动吸附Nb-ELISA相比灵敏度提高。基于XGBoost的多模态融合提高了定量准确性，SHAP分析阐释了模态贡献。在加标婴儿配方奶粉样品中，回收率范围为92.1%-118%，变异系数低于5.98%，证实了可接受的基质耐受性和分析可靠性。

3. 摘要层面解读

研究对象：自组装PD-L1纳米抗体(KN035)蛋白纳米颗粒用于多重药物偶联和化疗-免疫协同治疗。支架类型：nanobody/VHH（KN035）。靶点：PD-L1。应用场景：肿瘤化学免疫协同治疗。主要方法：MT3-KN035融合蛋白设计→自组装纳米颗粒→溶酶体内化验证→醛基阿霉素酸敏感偶联→体内外抗肿瘤功效。主要发现：(1) MT3-KN035自组装成纳米颗粒且不损害抗原结合；(2) 纳米颗粒从PD-L1阳性细胞表面内化至溶酶体；(3) 实现多重药物偶联；(4) MT3-KN035-DOXHigh显著抗肿瘤+免疫细胞浸润增强；(5) 化疗与免疫检查点阻断协同。与传统抗体相比的优势：利用纳米抗体小尺寸实现自组装纳米颗粒构建，解决NDCs内化瓶颈。为什么值得关注：创新性地解决了NDC内化效率关键瓶颈，且融合了免疫检查点抑制和化疗双重机制。

4. 全文精读分析

未进行全文分析，原因：非OA / 无法合法访问全文。

5. 一句话评价

该研究巧妙利用纳米抗体作为"机制探针"，同时产出治疗候选分子和关键机制证据，发表于Alzheimer's & Dementia (Q1, JIF 6.8)，是本周最优文献之一。

文献 11

英文题目： Versatile Detection of Cellular Protein via Fluorescence Anisotropy.中文题目：通过荧光各向异性实现细胞蛋白的多功能检测作者：Tang Qing, Wei Yuan-Ping, Ma Ricky Ruiqi, et al.期刊：Advanced science (Weinheim, Baden-Wurttemberg, Germany) (Adv Sci (Weinh))发表时间：PMID：42439473DOI：10.1002/advs.76141PubMed 链接：https://pubmed.ncbi.nlm.nih.gov/42439473/期刊分区：Q1分区核验来源：数据来自2025年（2024JIF），ISSN/eISSN精确匹配高质量杂志参考目录OA 状态：非OAPMC ID：PMCPMC13360121PMC 全文链接：https://www.ncbi.nlm.nih.gov/pmc/articles/PMCPMC13360121/支架类型：nanobody/VHH靶点：见摘要应用方向：诊断/成像, 靶向降解, 筛选平台/方法推荐等级：★★ B

1. 原文摘要

Protein detection is a cornerstone of life science research. Here, we present Cell Lysate Fluorescence Anisotropy (CFAST), a versatile and accessible alternative cellular protein detection method. CFAST measures cellular protein levels through changes in fluorescence anisotropy of a long lifetime triangulenium dye-labeled nanobody probe. The minimal steps of centrifugation and nuclease incubation remove unwanted cellular components. We demonstrate that CFAST robustly detects cellular PARP1, MK2, and GFP protein levels. Coupling small molecule incubation and thermal shift with CFAST (thermal shift-CFAST) enables detection of cellular protein-small molecule interactions through quantification of thermally stabilized target protein. Thermal shift-CFAST successfully detects cellular PARP1 and MK2 inhibitor binding in a dose-dependent manner. High-throughput thermal shift-CFAST screening identified a small molecule binder of undruggable transcription factor SOX2. This screening method also enabled development of a bifunctional PROTAC that simultaneously degrades membrane-bound oncogene EGFR and inhibits immune modulating target HRH1. CFAST is rapid, taking a minimum of 2-3 hours to execute. It is also straightforward, utilizing common lab equipment and reasonably priced reagents. Our work suggests that CFAST is a viable alternative method to enhance protein detection as well as drug and probe discovery that is scalable, fast, and economical.

2. 摘要中文翻译

蛋白检测是生命科学研究的基石。本研究提出了细胞裂解物荧光各向异性(CFAST)，一种多功能且易用的替代性细胞蛋白检测方法。CFAST通过长寿命triangulenium染料标记的纳米抗体探针的荧光各向异性变化测量细胞蛋白水平。我们证明CFAST能稳健检测细胞PARP1、MK2和GFP蛋白水平。将小分子孵育和热转变与CFAST耦合（热转变-CFAST）可通过量化热稳定的靶蛋白来检测细胞蛋白-小分子相互作用。热转变-CFAST成功以剂量依赖性方式检测细胞PARP1和MK2抑制剂结合。高通量热转变-CFAST筛选鉴定了不可成药转录因子SOX2的小分子结合剂，并促成了同时降解EGFR并抑制HRH1的双功能PROTAC的开发。CFAST快速（最少2-3小时），使用常规实验室设备和合理价格的试剂。

3. 摘要层面解读

研究对象：纳米抗体在食品安全检测（阪崎肠杆菌）中的应用，聚焦定向固定和信号放大。支架类型：nanobody/VHH（AviTag位点特异性生物素化+噬菌体展示多价放大）。靶点：阪崎肠杆菌。应用场景：食品安全快速检测，婴儿配方奶粉质控。主要方法：AviTag生物素化→肽分子锁定向→噬菌体展示多价放大→荧光+比色双模态→XGBoost/SHAP数据融合。主要发现：(1) 定向固定+多价放大显著提高灵敏度；(2) 荧光LOD 6.70×10² CFU/mL；(3) 回收率92.1%-118%，CV<5.98%；(4) AI数据融合提高定量准确性。与传统抗体相比的优势：纳米抗体的高稳定性和可工程化性使其适合定向固定和噬菌体多价展示。为什么值得关注：发表于Food Chemistry (Q1, JIF 9.8)，将AI集成到纳米抗体检测平台，为智能食品安全检测提供了范例。

4. 全文精读分析

未进行全文分析，原因：非OA / 无法合法访问全文。

5. 一句话评价

该研究巧妙利用纳米抗体作为"机制探针"，同时产出治疗候选分子和关键机制证据，发表于Alzheimer's & Dementia (Q1, JIF 6.8)，是本周最优文献之一。

文献 12

英文题目： Probing the Role of Accessory Domains in Oxygen Stability of [FeFe]-Hydrogenases.中文题目：探究辅助结构域在[FeFe]-氢化酶氧稳定性中的作用作者：Alogaidi Abdulrahman, Carr Stephen B, Hudson Lucy, et al.期刊：Journal of the American Chemical Society (J Am Chem Soc)发表时间：PMID：42430233DOI：10.1021/jacs.6c05865PubMed 链接：https://pubmed.ncbi.nlm.nih.gov/42430233/期刊分区：Q1分区核验来源：数据来自2025年（2024JIF），ISSN/eISSN精确匹配高质量杂志参考目录OA 状态：非OA支架类型：其他蛋白支架靶点：见摘要应用方向：筛选平台/方法, 工程化/设计, 结构解析推荐等级：★★ B

1. 原文摘要

[FeFe]-hydrogenases are the fastest enzymes for hydrogen evolution, yet their irreversible inhibition by oxygen has thwarted their industrial use. CbA5H is an exception as its inhibition by oxygen is reversible. Protein scaffold rearrangement near the active site, allowing a ligand to coordinate the metal center in addition to the formation of a highly oxidized state of the metal center named Hinact, is the current hypothesis for CbA5H oxygen stability. However, the ligand identity has been disputed and there is no evidence to suggest that protein scaffold rearrangement is the sole reason for oxygen stability. Here, we investigate CbA5H oxygen stability by providing a high-resolution (1.96 Å) X-ray structure that shows that the protective ligand is a conserved cysteine thiol group, which directly coordinates the metal center. The local rearrangement also encompasses structural water molecules and the side chain of E341, associated with proton transfer. In addition, we illustrate that C236 and H245, located close to accessory iron sulfur clusters in the Fd domain, influence oxygen stability. We show that mutating these residues significantly decreases oxygen stability but not the ability to form Hinact. Variant C236A displays a slower inactivation rate, which we suggest is due to tuning the redox properties of one of the accessory iron sulfur clusters. We also show that the soluble ligand-binding β-grasp domain (SLBB) may not be required for oxygen stability by comparing CbA5H to a novel homolog lacking this domain. Collectively, these findings expand our understanding of oxygen stability in [FeFe]-hydrogenases.

2. 摘要中文翻译

[FeFe]-氢化酶是产氢最快的酶，但其被氧不可逆抑制阻碍了工业应用。CbA5H是一个例外，其氧抑制是可逆的。活性位点附近的蛋白支架重排，允许配体配位金属中心以及形成Hinact高度氧化态，是目前对CbA5H氧稳定性的假说。然而，配体身份存在争议，且没有证据表明蛋白支架重排是氧稳定性的唯一原因。本研究通过提供高分辨率(1.96 Å)X射线结构研究CbA5H氧稳定性，显示保护性配体是保守的半胱氨酸巯基，直接配位金属中心。此外，我们阐明位于Fd结构域辅助铁硫簇附近的C236和H245影响氧稳定性。这些残基的突变显著降低氧稳定性但不影响形成Hinact的能力。我们还通过将CbA5H与缺乏该结构域的新型同源物比较，表明SLBB结构域可能不是氧稳定性所必需的。

3. 摘要层面解读

研究对象：本研究以其他蛋白支架为核心，聚焦相关生物医学应用。

关键数据指标：

• 包含结构生物学数据

支架类型：其他蛋白支架应用场景：筛选平台/方法, 工程化/设计, 结构解析推荐理由：该文献发表于Q1区期刊（15.6），聚焦其他蛋白支架在筛选平台/方法, 工程化/设计, 结构解析的研究，具有较高的学术价值和参考意义。

4. 全文精读分析

未进行全文分析，原因：非OA / 无法合法访问全文。

5. 一句话评价

该研究在其他蛋白支架领域的筛选平台/方法, 工程化/设计, 结构解析方向做出了有意义的贡献。

文献 13

英文题目： Linker-optimized bivalent nanobodies combined with photothermal gold liposome nanocomposites for enhanced dual-mode lateral flow immunoassay.中文题目：连接子优化的二价纳米抗体联合光热金脂质体纳米复合物实现增强型双模态侧流免疫层析作者：Han Jinzhi, Liang Hongzhi, Luo Lin, et al.期刊：Biosensors & bioelectronics (Biosens Bioelectron)发表时间：PMID：42419080DOI：10.1016/j.bios.2026.119015PubMed 链接：https://pubmed.ncbi.nlm.nih.gov/42419080/期刊分区：Q1分区核验来源：数据来自2025年（2024JIF），ISSN/eISSN精确匹配高质量杂志参考目录OA 状态：非OA支架类型：nanobody/VHH靶点：见摘要应用方向：诊断/成像, 工程化/设计推荐等级：★★ B

1. 原文摘要

Lateral flow immunoassay (LFIA) has been widely used for rapid on-site analysis because of its simplicity, portability, and low cost. However, its performance in competitive assays, particularly for small molecule toxins, remains limited, as the properties of antibodies and the reliance on single-mode signal often lead to insufficient sensitivity and reliability. To address this challenge, we developed an enhanced colorimetric-photothermal LFIA by integrating linker-optimized bivalent nanobodies (BvNbs) and gold-liposome nanocomposites (Au-LNCs). Using tetrodotoxin (TTX) as a representative analyte, a series of BvNbs with different linker lengths were constructed. Molecular docking and molecular dynamics simulations further demonstrated that linker length modulates BvNbs detection performance by regulating conformational stability, local flexibility, and persistent interactions with free target molecules. In parallel, photothermal Au-LNCs were prepared, which exhibited broadband near-infrared absorption and a photothermal conversion efficiency as high as 78.06%. The resulting LFIA achieved a photothermal LOD of 1.89 ng/mL, corresponding to an approximately 10.7-fold improvement in sensitivity compared with conventional colloidal gold-based LFIA, while maintaining good reliability in real samples. Overall, this study provides mechanistic insight into the rational design of BvNbs and a promising strategy for improving LFIA performance.

2. 摘要中文翻译

侧流免疫层析(LFIA)因其简便、便携和低成本而被广泛用于现场快速分析。然而，其在竞争性检测（特别是小分子毒素）中的性能仍然有限，因为抗体特性和单一模态信号常导致灵敏度和可靠性不足。为应对这一挑战，我们通过整合连接子优化的二价纳米抗体(BvNbs)和金脂质体纳米复合物(Au-LNCs)，开发了一种增强型比色-光热LFIA。以河豚毒素(TTX)为代表分析物，构建了一系列不同连接子长度的BvNbs。分子对接和分子动力学模拟进一步证明，连接子长度通过调节构象稳定性、局部柔性和与游离靶分子的持续相互作用来调控BvNbs的检测性能。Au-LNCs展示高达78.06%的光热转换效率。所得LFIA达到光热LOD 1.89 ng/mL，与传统胶体金LFIA相比灵敏度提高约10.7倍。

3. 摘要层面解读

研究对象：基于荧光各向异性纳米抗体探针的细胞蛋白检测平台(CFAST)及其在药物发现中的应用。支架类型：nanobody/VHH（triangulenium染料标记的纳米抗体荧光探针）。靶点：PARP1, MK2, GFP, SOX2, EGFR。应用场景：蛋白检测、药物靶点验证、PROTAC开发。主要方法：长寿命染料标记纳米抗体→荧光各向异性→热转变耦合→高通量筛选→PROTAC设计。主要发现：(1) CFAST可检测多种细胞蛋白；(2) 热转变-CFAST检测蛋白-小分子相互作用；(3) 高通量筛选发现SOX2(不可成药靶点)的结合剂；(4) 促成了EGFR/HRH1双靶PROTAC的开发；(5) 快速(2-3h)、低成本、可扩展。与传统方法相比的优势：CFAST利用纳米抗体的高特异性实现WB/ELISA的替代方案，且能直接检测不可成药靶点的小分子结合。为什么值得关注：发表于Advanced Science (Q1, JIF 14.1)，为不可成药靶点的药物发现提供了全新筛选平台。

4. 全文精读分析

未进行全文分析，原因：非OA / 无法合法访问全文。

5. 一句话评价

该研究巧妙利用纳米抗体作为"机制探针"，同时产出治疗候选分子和关键机制证据，发表于Alzheimer's & Dementia (Q1, JIF 6.8)，是本周最优文献之一。

文献 14

英文题目： Novel Photo-Driven Activated Enzyme-Titanium Nanobiohybrids for Photocatalytic Applications.中文题目：新型光驱动活化酶-钛纳米生物杂化物用于光催化应用作者：Palla Francesca, Garcia-Sanz Carla, Marciello Marzia, Palomo Jose M期刊：Nanomaterials (Basel, Switzerland) (Nanomaterials (Basel))发表时间：PMID：42439761DOI：10.3390/nano16130823PubMed 链接：https://pubmed.ncbi.nlm.nih.gov/42439761/期刊分区：Q2分区核验来源：数据来自2025年（2024JIF），ISSN/eISSN精确匹配高质量杂志参考目录OA 状态：非OAPMC ID：PMCPMC13363157PMC 全文链接：https://www.ncbi.nlm.nih.gov/pmc/articles/PMCPMC13363157/支架类型：其他蛋白支架靶点：见摘要应用方向：药物递送, 工程化/设计, 结构解析, 治疗应用推荐等级：★★ B

1. 原文摘要

This work reports the development of innovative enzyme-titanium nanobiohybrids synthesized via a protein-assisted approach to obtain efficient and sustainable photocatalysts for environmental remediation. By addressing the limitations of conventional TiO2 nanoparticle synthesis, this strategy enables controlled material properties under milder, potentially scalable conditions for enhanced ROS-driven degradation of persistent dye pollutants. This work employs a bio-assisted synthesis approach using β-glucosidase as a protein scaffold, TiCl4 as the titanium precursor, and H2O2 in bicarbonate buffer at room temperature, eliminating the need for harsh conditions and high temperatures. The biological moiety guides the nanoparticle formation, controlling size and morphology while preventing aggregation, all performed under mild conditions. X-ray diffraction determined that the Ti hybrid was composed of TiO2 brookite species. TEM analyses demonstrated the formation of well-dispersed nanostructures of around 700 nm. The resulting nanobiohybrids showed excellent photocatalytic activity, achieving >99% Rhodamine B degradation under UV light in only 1 h compared to visible light. The catalyst was capable of degrading Rhodamine B at a concentration approximately 36 times above the recommended threshold for water. Furthermore, a preactivation of the catalyst by direct exposition of it to UV-395 nm light greatly enhanced the efficiency in the photocatalytic process, being inactive in visible light. The Ti-enzyme hybrid showed excellent recyclability over five consecutive cycles and retained good activity after storage, demonstrating its stability. This study introduces a sustainable and efficient route for synthesizing Ti-based nanobiohybrids, providing a promising strategy for advanced photocatalytic applications in water treatment and environmental remediation.

2. 摘要中文翻译

本工作报告了通过蛋白辅助方法合成的创新酶-钛纳米生物杂化物的开发，以获得用于环境修复的高效可持续光催化剂。通过解决传统TiO2纳米颗粒合成的局限性，该策略在更温和、潜在可扩展的条件下实现可控材料性质。本研究采用生物辅助合成方法，使用β-葡萄糖苷酶作为蛋白支架，TiCl4作为钛前体，于室温反应，消除了对苛刻条件和高温的需求。生物组分指导纳米颗粒形成，控制尺寸和形态同时防止聚集。X射线衍射确定Ti杂化物由TiO2板钛矿组成。TEM分析展示了约700 nm的良好分散纳米结构。所得纳米生物杂化物在紫外光下1小时内实现>99%罗丹明B降解。催化剂能在约36倍于推荐水环境阈值的浓度下降解罗丹明B。Ti-酶杂化物在五个连续循环中展示出色的可回收性。

3. 摘要层面解读

研究对象：本研究以其他蛋白支架为核心，聚焦药物递送系统开发。

关键数据指标：

• 包含结构生物学数据

支架类型：其他蛋白支架应用场景：药物递送, 工程化/设计, 结构解析, 治疗应用推荐理由：该文献发表于Q2区期刊（4.3），聚焦其他蛋白支架在药物递送, 工程化/设计, 结构解析, 治疗应用的研究，具有较高的学术价值和参考意义。

4. 全文精读分析

未进行全文分析，原因：非OA / 无法合法访问全文。

5. 一句话评价

该研究利用其他蛋白支架实现靶向药物递送，为精准医学递送系统提供了工程化思路。

文献 15

英文题目： A neuraminidase-targeted nanobody confers broad protection against influenza B virus.中文题目：靶向神经氨酸酶的纳米抗体赋予针对乙型流感病毒的广谱保护作者：Jia Hang, Lin Chaohui, Guo Yinghao, et al.期刊：Journal of virology (J Virol)发表时间：PMID：42429627DOI：10.1128/jvi.00762-26PubMed 链接：https://pubmed.ncbi.nlm.nih.gov/42429627/期刊分区：Q2分区核验来源：数据来自2025年（2024JIF），ISSN/eISSN精确匹配高质量杂志参考目录OA 状态：非OA支架类型：nanobody/VHH靶点：见摘要应用方向：感染性疾病, 结构解析, 治疗应用推荐等级：★★ B

1. 原文摘要

UNLABELLED: Influenza B virus (IBV) exhibits antigenic diversity and significantly contributes to the annual burden of influenza-related disease, posing substantial impacts on global public health and the economy. In this study, we focused on the neuraminidase (NA) of IBV, immunized an alpaca with tetrameric IBV NA, and identified a series of nanobodies with a common feature of the "DYR" motif in CDR3, exhibiting broad inhibitory activity against diverse NAs of IBV. Among these, the most potent VHH5 broadly inhibits NA from multiple representative strains across ancestral, B/Yamagata/16/88-like, and B/Victoria/2/87-like lineages. Moreover, fusing VHH5 to a human immunoglobulin G1 Fc domain significantly increased its antiviral potency in vitro, with the 50% inhibitory concentration in the low nanomolar range. Structural modeling and molecular dynamics simulations revealed that the "DYR" motif within the elongated CDR3 loop of VHH5 penetrates the catalytic pocket and engages the highly conserved catalytic site of IBV NA. Experimental mutagenesis analysis of the predicted interface further supported this binding model. Furthermore, the VHH5-Fc protects mice from the lethal challenge with a high dose of the IBV-2024 virus in both prophylactic and therapeutic settings. Our findings highlight the potential of the Fc-fused VHH5 antibody in controlling influenza B virus infections. IMPORTANCE: Although influenza B viruses (IBVs) account for a substantial proportion of seasonal influenza virus infections, they have received comparatively less research attention. The small size and flexible binding modes of nanobodies enable them to access cryptic or recessed epitopes, supporting their development as potent clinical therapeutics. Here, we report the identification of VHH5, a nanobody targeting conserved residues within the neuraminidase active site of the influenza B virus, conferring broad inhibitory activity. Moreover, Fc-fused VHH5 enhanced antiviral potency in vitro and provided robust protection against lethal IBV challenge in mice. Together, these findings establish VHH5-Fc as a promising therapeutic candidate with potent and broad-spectrum activity against antigenically diverse IBV strains.

2. 摘要中文翻译

乙型流感病毒(IBV)展示抗原多样性，对全球公共卫生和经济造成实质性影响。本研究聚焦于IBV的神经氨酸酶(NA)，用四聚体IBV NA免疫羊驼，鉴定出一系列在CDR3中具有"DYR"基序共同特征的纳米抗体，展示对IBV多种NA的广谱抑制活性。其中，最有效的VHH5广泛抑制来自祖系、B/Yamagata/16/88-样和B/Victoria/2/87-样谱系的多种代表性毒株的NA。将VHH5与人IgG1 Fc结构域融合显著增强了其体外抗病毒效力，50%抑制浓度在低纳摩尔范围。结构建模和分子动力学模拟揭示，VHH5延长的CDR3环中的"DYR"基序穿透催化口袋并结合IBV NA的高度保守催化位点。VHH5-Fc在预防和治疗设置中均保护小鼠免受高剂量IBV-2024病毒的致死性攻击。

3. 摘要层面解读

研究对象：[FeFe]-氢化酶的蛋白骨架结构与氧稳定性机制。支架类型：其他蛋白支架（天然酶蛋白骨架）。靶点：不适用（基础酶学）。应用场景：生物催化/工业酶工程。主要方法：高分辨率X射线晶体学(1.96 Å)→定点突变→酶活性测定→氧化还原性质分析→同源物比较。主要发现：(1) 保护性配体为半胱氨酸巯基；(2) C236和H245影响氧稳定性；(3) C236A突变减缓失活速率。注意：该文献核心是酶学而非蛋白结合支架，关键词命中来自"protein scaffold"的酶学语境，与纳米抗体/结合支架的直接相关性有限。

4. 全文精读分析

未进行全文分析，原因：非OA / 无法合法访问全文。

5. 一句话评价

该研究将nanobody/VHH用于感染性疾病的干预，为抗感染药物/疫苗开发提供了新的分子工具。

文献 16

英文题目： Delving into the innate and adaptive immunity of camelids: a paradigm of interspecies adaptation and evolutionary innovation.中文题目：探究骆驼科动物的先天性和适应性免疫：种间适应与进化创新的范式作者：Ramesh Remya Pg, Premraj Avinash, Yasmin Hadida, et al.期刊：Frontiers in immunology (Front Immunol)发表时间：PMID：42421968DOI：10.3389/fimmu.2026.1833289PubMed 链接：https://pubmed.ncbi.nlm.nih.gov/42421968/期刊分区：Q1分区核验来源：数据来自2025年（2024JIF），ISSN/eISSN精确匹配高质量杂志参考目录OA 状态：非OAPMC ID：PMCPMC13343275PMC 全文链接：https://www.ncbi.nlm.nih.gov/pmc/articles/PMCPMC13343275/支架类型：nanobody/VHH靶点：见摘要应用方向：诊断/成像, 感染性疾病, 放射性配体治疗, 治疗应用推荐等级：★ C

1. 原文摘要

Camelids have evolved to survive some of the most challenging climatic conditions on our planet and are resilient to physiological stress such as temperature extremes, drought, storms, intense ultraviolet radiation, dehydration, and starvation. They exhibit remarkable resistance to several diseases that severely affect other livestock including tetanus, foot-and-mouth disease, and bovine spongiform encephalopathy. The robust nature of the camelid immune system, which maintains functionality under extreme conditions, is remarkable. The special features of the camelid immune system include differences (when compared to ruminants) in the distribution and anatomy of their lymphoid organs. The innate immune system merits further investigation, though potent antimicrobial peptides have been identified in camelid milk. It is in the adaptive immune response that the most distinctive aspects of the camelid immune system are seen, especially, the presence of heavy chain-only antibodies, somatic hypermutation of T cell receptors; in the dromedary, a significant number of γδ T cells. In this review, the interplay between innate and adaptive immunity in camelids is examined, highlighting their functions in systemic and mucosal immune defense. An understanding of these adaptations is important for the development of innovative biomedical applications, such as nanobody-based diagnostics and therapeutics. In addition, dromedary camels are the main likely animal reservoir for the Middle East Respiratory Syndrome Coronavirus (MERS-CoV), an emerging zoonotic pathogen with potential for large-scale human spillover. Finally, as climate change is likely to result in increased environmental stress worldwide, a comparison of how the immune system in different species has adapted to their environment will be important.

2. 摘要中文翻译

骆驼科动物已进化出在地球上最具挑战性气候条件下生存的能力，对极端温度、干旱、风暴、强紫外线辐射、脱水和饥饿等生理压力具有韧性。它们展示出对几种严重影响其他家畜的疾病（包括破伤风、口蹄疫和牛海绵状脑病）的显著抵抗力。正是在适应性免疫反应中，骆驼科免疫系统最独特的方面得以展现，特别是重链抗体的存在、T细胞受体的体细胞超突变；在单峰驼中，还有大量γδ T细胞。本综述审视了骆驼科动物先天性和适应性免疫之间的相互作用，突出它们在全身和粘膜免疫防御中的功能。理解这些适应对于开发创新生物医学应用（如基于纳米抗体的诊断和治疗）至关重要。此外，单峰驼是MERS-CoV的主要可能动物宿主。

3. 摘要层面解读

研究对象：连接子长度优化的二价纳米抗体在侧流免疫层析检测中的性能优化。支架类型：nanobody/VHH（二价纳米抗体BvNbs，不同连接子长度）。靶点：河豚毒素(TTX)。应用场景：食品安全/毒素快速检测。主要方法：二价纳米抗体构建(不同连接子)→分子对接+MD模拟→Au-LNCs光热材料→双模态LFIA。主要发现：(1) 连接子长度调控二价纳米抗体的构象稳定性和靶标结合持续性；(2) Au-LNCs光热转换效率高达78.06%；(3) 光热LOD 1.89 ng/mL，灵敏度提高10.7倍；(4) MD模拟提供了连接子设计的机制指导。与传统抗体相比的优势：纳米抗体更适合构建多价格式，连接子优化提升亲和力和检测灵敏度。为什么值得关注：发表于Biosensors & Bioelectronics (Q1, JIF 10.5)，将连接子工程的机制理解与实用检测性能结合，为多价纳米抗体设计提供了可推广的方法论。

4. 全文精读分析

未进行全文分析，原因：非OA / 无法合法访问全文。

5. 一句话评价

该研究将纳米抗体用于放射性配体治疗，展示了VHH在肿瘤靶向放疗中的临床转化潜力。

文献 17

英文题目： Multifunctional biodegradable nanogels derived from well-defined block copolymers for precision drug delivery.中文题目：源自明确嵌段共聚物的多功能可生物降解纳米凝胶用于精准药物递送作者：Fuchs Alexander, Nuhn Lutz期刊：Journal of controlled release : official journal of the Controlled Release Society (J Control Release)发表时间：PMID：42034267DOI：10.1016/j.jconrel.2026.114952PubMed 链接：https://pubmed.ncbi.nlm.nih.gov/42034267/期刊分区：Q1分区核验来源：数据来自2025年（2024JIF），ISSN/eISSN精确匹配高质量杂志参考目录OA 状态：非OA支架类型：nanobody/VHH靶点：见摘要应用方向：药物递送, 治疗应用推荐等级：★ C

1. 原文摘要

To fully harness the potential of advanced therapeutics, various delivery scenarios must be handled. Polymer-based, core-crosslinked, fully hydrophilic nanogels are a promising platform to tackle these drug delivery challenges. In contrast to micellar delivery systems, nanogels have a stable morphology even in vivo. And compared to lipid-based systems, they feature no innate immune activity and are chemically more easily and precisely modifiable. Over the years we have introduced a stepwise synthesis strategy starting from monomer synthesis, block copolymerization and self-assembly, followed by further functionalization as well as core-crosslinking. This robust process allows for customization of the final nanogel during every step. Nanogels can transport a wide array of drugs, ranging from covalently bound or non-covalently encapsulated small molecules to electrostatically bound nucleic acids. Additionally, targeting motives like carbohydrates, peptides or nanobodies can be attached to the surface. The current generation of nanogels is importantly biodegradable and features various modes of disassembly that respond to different environmental triggers. We foresee a promising future for this evolving platform using the toolbox that chemistry provides to foster drug co-delivery, enhance degradability and adapt to future trends such as personalized medicine and AI.

2. 摘要中文翻译

为充分利用先进治疗药物的潜力，必须应对多种递送场景。基于聚合物的核交联全亲水纳米凝胶是应对这些药物递送挑战的有前景平台。与胶束递送系统相比，纳米凝胶在体内也具有稳定形态。与脂质系统相比，它们无先天免疫活性且在化学上更易精确修饰。我们引入了一种逐步合成策略，从单体合成、嵌段共聚和自组装开始，然后进行进一步功能化和核交联。纳米凝胶可运输多种药物，从共价结合或非共价封装的小分子到静电结合的核酸。此外，靶向基序如碳水化合物、肽或纳米抗体可附着于表面。当前一代纳米凝胶可生物降解，并具有响应不同环境触发因素的各种解体模式。

3. 摘要层面解读

注意：该文献核心是材料化学/环境催化，"protein scaffold"指天然酶作为合成模板，与蛋白结合支架研发无直接关联。保留仅因高水平期刊参考价值。

4. 全文精读分析

未进行全文分析，原因：非OA / 无法合法访问全文。

5. 一句话评价

该研究利用nanobody/VHH实现靶向药物递送，为精准医学递送系统提供了工程化思路。

文献 18

英文题目： Molecular PET imaging of tumor-associated macrophages in precision oncology.中文题目：精准肿瘤学中肿瘤相关巨噬细胞的分子PET成像作者：Wang Yong, Liu Baoyan, Patel Harsh, et al.期刊：Cancer letters (Cancer Lett)发表时间：PMID：42019605DOI：10.1016/j.canlet.2026.218526PubMed 链接：https://pubmed.ncbi.nlm.nih.gov/42019605/期刊分区：Q1分区核验来源：数据来自2025年（2024JIF），ISSN/eISSN精确匹配高质量杂志参考目录OA 状态：非OA支架类型：nanobody/VHH靶点：见摘要应用方向：肿瘤治疗, 诊断/成像, 药物递送, 免疫治疗, 治疗应用推荐等级：★ C

1. 原文摘要

Tumor-associated macrophages (TAMs) represent a dominant, plastic component of the tumor microenvironment (TME) that orchestrates immunosuppression, angiogenesis, and therapeutic resistance. Since static biopsies fail to capture the spatiotemporal heterogeneity and dynamic phenotypic evolution of TAMs (e.g., M1/M2 polarization), non-invasive imaging is critical. This review systematically critiques the evolution of Positron Emission Tomography (PET) strategies for TAM quantification, classifying innovations into metabolic, functional, and molecular approaches. Moving beyond the limitations of indirect methods-such as [18F]FDG and "Trojan horse" nanoparticles constrained by mononuclear phagocyte system (MPS) sequestration-we emphasize the paradigm shift toward high-affinity molecular probes. These target specific biomarkers (e.g., CD206, CD163, CSF1R) and recruitment pathways (e.g., CCR2). We particularly highlight the clinical potential of nanobody- and peptide-based tracers, which demonstrate superior tumor penetration and rapid clearance compared to full-sized antibodies. Concluding with an analysis of translational hurdles, such as interspecies marker discordance, we propose future directions that integrate theranostics, spatial transcriptomics, and AI-driven radiomics. Ultimately, molecular TAM-PET imaging is poised to evolve from an experimental tool into a precision oncology platform for patient stratification and monitoring of immunomodulatory therapies.

2. 摘要中文翻译

肿瘤相关巨噬细胞(TAMs)是肿瘤微环境(TME)中主导性的可塑性组分，协调免疫抑制、血管生成和治疗抵抗。由于静态活检无法捕捉TAMs的时空异质性和动态表型演变，非侵入性成像至关重要。本综述系统审视了用于TAM定量的PET策略的演变，将创新分为代谢、功能和分子方法。我们特别强调基于纳米抗体和肽的示踪剂的临床潜力，它们与全长抗体相比展示优越的肿瘤穿透和快速清除。最后分析转化障碍，如种间标志物差异，我们提出整合诊疗一体化、空间转录组学和AI驱动放射组学的未来方向。

3. 摘要层面解读

研究对象：靶向乙型流感病毒NA的广谱中和纳米抗体的筛选及体内外验证。支架类型：nanobody/VHH（VHH5-Fc）。靶点：IBV NA催化位点。关键发现：DYR基序共性+催化口袋穿透结合+小鼠致死保护，发表于J Virol (Q2, JIF 3.8)。与传统抗体相比的优势：长CDR3穿透NA深凹催化口袋——传统mAb难以实现。

4. 全文精读分析

未进行全文分析，原因：非OA / 无法合法访问全文。

5. 一句话评价

该研究巧妙利用纳米抗体作为"机制探针"，同时产出治疗候选分子和关键机制证据，发表于Alzheimer's & Dementia (Q1, JIF 6.8)，是本周最优文献之一。

文献 19

英文题目： Prostate-specific membrane antigen based diagnostic and therapeutic integration for prostate cancer management.中文题目：基于前列腺特异性膜抗原的前列腺癌诊疗一体化管理作者：Dixit Tanu, Sawardekar Mansi, Verma Tanushree, Sreeja P, Ravindran Selvan期刊：Discover oncology (Discov Oncol)发表时间：PMID：42437859DOI：10.1007/s12672-026-05554-4PubMed 链接：https://pubmed.ncbi.nlm.nih.gov/42437859/期刊分区：Q2分区核验来源：数据来自2025年（2024JIF），ISSN/eISSN精确匹配高质量杂志参考目录OA 状态：非OA支架类型：nanobody/VHH靶点：见摘要应用方向：肿瘤治疗, 诊断/成像, 双/多特异, 工程化/设计, 放射性配体治疗, 治疗应用推荐等级：★ C

1. 原文摘要

Prostate-specific membrane antigen (PSMA)-based theragnostics has transformed precision oncology by integrating molecular imaging and targeted radionuclide therapy in prostate cancer (PCa). This review outlines the mechanistic rationale of PSMA targeting, radiopharmaceutical design, and diagnostic applications of 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) imaging. The sensitivity and specificity of 68Ga-PSMA-11 PET/CT imaging are higher than those of conventional imaging. Randomized phase III trials have demonstrated that 177Lu-PSMA-617 confers survival benefits to patients with metastatic castration-resistant PCa. Meanwhile, emerging α-emitter therapies, such as 225Ac-PSMA-617, exert potent cytotoxic effects in resistant disease but are associated with xerostomia as a dose-limiting toxicity and production constraints. Dosimetry, patient selection, and toxicity management are critical to optimize therapeutic outcomes. Novel approaches, including bispecific antibodies and nanobody-based agents, along with combination regimens and ongoing randomized trials, are expected to refine treatment strategies and extend applications. PSMA-based theragnostics are associated with challenges related to access, isotope supply, and standardized protocols. However, PSMA-based theragnostics represents a paradigm shift toward individualized, biology-driven cancer care, setting the benchmark for future theragnostic developments across oncology.

2. 摘要中文翻译

基于PSMA的诊疗一体化通过整合分子成像和靶向放射性核素治疗，改变了精准肿瘤学在前列腺癌中的格局。本综述概述了PSMA靶向的机制原理、放射性药物设计以及⁶⁸Ga-PSMA-11 PET/CT成像的诊断应用。随机III期试验已证明¹⁷⁷Lu-PSMA-617为转移性去势抵抗性PCa患者带来生存获益。新兴的α放射源治疗如²²⁵Ac-PSMA-617在耐药疾病中发挥强效细胞毒作用。包括双特异性抗体和基于纳米抗体的药物在内的新方法，以及联合方案和正在进行的随机试验，有望完善治疗策略并扩展应用。PSMA诊疗一体化代表着向个体化生物学驱动癌症治疗的范式转变。

3. 摘要层面解读

注意：高质量综述（Front Immunol, Q1, JIF 5.9），系统总结了骆驼科免疫系统独特特征（重链抗体、TCR超突变等），为纳米抗体研发提供进化生物学背景。不含新实验数据。

4. 全文精读分析

未进行全文分析，原因：非OA / 无法合法访问全文。

5. 一句话评价

该研究将纳米抗体用于放射性配体治疗，展示了VHH在肿瘤靶向放疗中的临床转化潜力。

文献 20

英文题目： Asthma at the crossroads: From anti-TNF-α setbacks to next-generation biologics targeting type 1 and type 2 inflammation.中文题目：哮喘的十字路口：从抗TNF-α挫折到靶向1型和2型炎症的下一代生物制剂作者：Patel Vaibhavkumar, Khera Nikita, Singh Gurvir, Khalid Ansari Md Asif期刊：Respiratory medicine (Respir Med)发表时间：PMID：42425314DOI：10.1016/j.rmed.2026.109033PubMed 链接：https://pubmed.ncbi.nlm.nih.gov/42425314/期刊分区：Q2分区核验来源：数据来自2025年（2024JIF），ISSN/eISSN精确匹配高质量杂志参考目录OA 状态：非OA支架类型：nanobody/VHH靶点：见摘要应用方向：免疫治疗, 治疗应用推荐等级：★ C

1. 原文摘要

Severe asthma remains a major unmet clinical challenge due to its marked immunological heterogeneity and the limited efficacy of current therapies in non-Type 2 inflammatory endotypes. Although biologics targeting IL-4, IL-5, and IL-13 have significantly improved outcomes in eosinophilic asthma, therapeutic options for Type 1 and mixed inflammatory phenotypes remain inadequate. The failure of anti-TNF-α therapies highlighted critical translational barriers including cytokine redundancy, insufficient endotype stratification, and systemic safety concerns, thereby reshaping the direction of respiratory immunopharmacology toward precision-guided intervention strategies. This review critically examines the immunobiology of Type 1 and Type 2 inflammation, evaluates the mechanistic and clinical lessons derived from anti-TNF-α trials, and discusses emerging therapeutic platforms including nanobodies, RNA-based therapeutics, gene-editing technologies, cell-based immunotherapies, and advanced pulmonary delivery systems. Furthermore, the review highlights the growing role of multi-omics biomarkers, microbiome profiling, and artificial intelligence in enabling adaptive and personalized asthma management. Collectively, these advances support a transition from generalized cytokine blockade toward integrated immune-network modulation for severe asthma across diverse inflammatory endotypes.

2. 摘要中文翻译

重度哮喘由于其显著的免疫学异质性和当前疗法在非2型炎症内型中的有限疗效，仍然是一个主要的未满足临床需求。抗TNF-α治疗的失败凸显了关键的转化障碍，包括细胞因子冗余、内型分层不足和全身安全性问题。本综述批判性地审视了1型和2型炎症的免疫生物学，评估了从抗TNF-α试验中获得的机制和临床教训，并讨论了新兴治疗平台，包括纳米抗体、基于RNA的疗法、基因编辑技术、细胞免疫疗法和先进肺部递送系统。这些进展支持从广义细胞因子阻断向跨不同炎症内型的集成免疫网络调节的转变。

3. 摘要层面解读

注意：高水平综述（J Control Release, Q1, JIF 11.5），聚焦纳米凝胶药物递送平台，纳米抗体作为表面靶向配体策略被提及，非核心研究内容。

4. 全文精读分析

未进行全文分析，原因：非OA / 无法合法访问全文。

5. 一句话评价

该研究在nanobody/VHH领域的免疫治疗, 治疗应用方向做出了有意义的贡献。

文献 21

英文题目： Injectable bioactive hydrogels as pharmacological drug delivery platforms for post-myocardial infarction cardiac repair: therapeutic cargo engineering, stimuli-responsive release mechanisms, and translational perspectives.中文题目：可注射生物活性水凝胶作为心肌梗死后心脏修复的药理药物递送平台作者：El-Sehrawy Amr Ali Mohamed Abdelgawwad, Alkhayyat Safa, Baig Mirza R, et al.期刊：Naunyn-Schmiedeberg's archives of pharmacology (Naunyn Schmiedebergs Arch Pharmacol)发表时间：PMID：42414695DOI：10.1007/s00210-026-05604-2PubMed 链接：https://pubmed.ncbi.nlm.nih.gov/42414695/期刊分区：Q2分区核验来源：数据来自2025年（2024JIF），ISSN/eISSN精确匹配高质量杂志参考目录OA 状态：非OA支架类型：nanobody/VHH靶点：见摘要应用方向：药物递送, 免疫治疗, 工程化/设计, 治疗应用推荐等级：★ C

1. 原文摘要

This review evaluates injectable bioactive hydrogels as localized pharmacological platforms for post-myocardial infarction (MI) cardiac repair, focusing on therapeutic cargo engineering, stimuli-responsive release systems, mechanistic signaling pathways, and translational potential. A critical narrative synthesis was conducted drawing upon the most recent original research published in leading journals in the field, emphasizing hydrogel composition, pharmacological cargo classes, release mechanisms, molecular targets, animal models, and clinical evidence. The review integrates studies involving small molecules, exosomes, conductive nanomaterials, nanobodies, extracellular matrix-derived systems, and gene delivery vectors. Injectable hydrogels demonstrated the capacity to provide spatially localized and temporally controlled therapy within the infarcted myocardium. Stimuli-responsive systems exploiting pH, reactive oxygen species, and enzymatic microenvironments enabled phase-matched therapeutic release. Major pharmacological effects included macrophage immunomodulation, angiogenesis promotion, oxidative stress reduction, fibrosis attenuation, and restoration of electrical conductivity. Convergent signaling pathways across studies included PI3K/AKT, AMPK-mTOR, VEGF, and TGF-β-related networks. Preclinical studies consistently reported improvements in ventricular remodeling and cardiac function, while early clinical translation with VentriGel established feasibility and procedural safety in human patients. Injectable bioactive hydrogels represent a promising pharmacological strategy for post-MI cardiac repair by integrating biomaterial engineering with localized multi-dimensional drug delivery. Despite substantial preclinical progress, challenges including long-term safety, mechanistic standardization, large-animal validation, and regulatory complexity remain critical barriers to clinical translation.

2. 摘要中文翻译

本综述评估了可注射生物活性水凝胶作为心肌梗死后心脏修复的局部药理学平台，聚焦治疗载药工程、刺激响应释放系统、机制信号通路和转化潜力。综述整合了涉及小分子、外泌体、导电纳米材料、纳米抗体、细胞外基质衍生系统和基因递送载体的研究。可注射水凝胶展示了在梗死心肌内提供空间定位和时间控制治疗的能力。利用pH、活性氧和酶微环境的刺激响应系统实现了时相匹配的治疗释放。主要药理学效应包括巨噬细胞免疫调节、血管生成促进、氧化应激减轻、纤维化减弱和电导恢复。尽管临床前进展显著，长期安全性、机制标准化等挑战仍然是临床转化的关键障碍。

3. 摘要层面解读

注意：高水平综述（Cancer Lett, Q1, JIF 10.1），明确肯定纳米抗体作为优选PET示踪剂支架（优越肿瘤穿透+快速清除），为纳米抗体诊断应用提供方向性指导。

4. 全文精读分析

未进行全文分析，原因：非OA / 无法合法访问全文。

5. 一句话评价

该研究利用nanobody/VHH实现靶向药物递送，为精准医学递送系统提供了工程化思路。

三、本周重点趋势总结

1. nanobody/VHH 持续占据主导地位

本周21篇Q1/Q2文献中，18篇（86%）以nanobody/VHH为核心支架，其余分别为affibody（1篇）和其他蛋白支架（2篇）。VHH在多个方向同时发力：

• 免疫治疗：Nature Communications上的三特异性IL-2R VHH激动剂（PMID 42431912）是本周最高水平文献，展示了几何构型优化对多特异性VHH设计的核心重要性。
• 神经疾病：抗Aβ纳米抗体-Fc融合蛋白（PMID 42444752）巧妙利用纳米抗体作为机制探针，同时验证了Fc效应功能在AD免疫治疗中的必要性。
• 感染性疾病：H9N2禽流感（PMID 42435874）、HIV-1（PMID 42443510）和乙型流感（PMID 42429627）三项研究从不同角度展示了VHH在抗病毒领域的价值。

2. 放射性配体治疗与诊疗一体化兴起

点击化学驱动的HER2纳米抗体通用标记平台（PMID 42419170）是本周亮点——单一VHH用4种同位素通用标记，兼顾PET/SPECT成像和¹⁷⁷Lu治疗，代表了纳米抗体诊疗一体化的最新进展。

3. AI/计算方法深度融合

本周多项研究将AI/计算方法深度整合：

• AlphaFold3辅助预测纳米抗体候选分子（PMID 42435874）
• ESM-2蛋白语言模型预测VHH可开发性（PMID 42420197，841 VHHs数据集）
• MD模拟指导二价纳米抗体连接子设计（PMID 42419080）
• XGBoost/SHAP多模态数据融合（PMID 42447597）

4. 检测与诊断平台创新

CFAST（PMID 42439473, Advanced Science）是本周方法论最大亮点——利用荧光各向异性纳米抗体探针实现不可成药靶点（SOX2）的药物筛选，且衍生了双靶PROTAC。该平台具有快速(2-3h)、低成本、可扩展的优势。

5. affibody的独特贡献

唯一affibody文献（PMID 42413707）发现HPV16E7特异性affitoxin通过不依赖caspase-3的GSDME焦亡途径杀伤肿瘤，为胞内靶向affibody-toxin研发提供了新机制范式。

6. 兽医应用新方向

猫CD3纳米抗体（PMID 42414706）开辟了兽医肿瘤学的纳米抗体应用方向。

7. 值得追踪的方向

• 三/多特异性VHH抗体的几何优化设计策略（Nat Commun团队）
• TRIM21/VHH-Fc胞内降解系统（Trim-Away策略在抗病毒中的扩展）
• CFAST高通量筛选平台（不可成药靶点药物发现的潜在工具）
• 点击化学+纳米抗体诊疗一体化的临床转化进展
• AI辅助VHH设计（AlphaFold3/ESM-2/MD模拟的集成应用）

四、待核验或排除文献

以下5篇文献在初始检索中命中但未能纳入高质量文献列表：

排除说明：

• 本周无假阳性排除（FNDC5/irisin/ELFN2相关文章在本周检索中已由搜索脚本自动过滤）。
• bioRxiv预印本（2篇）虽内容相关但不符合周报纳入标准。
• 3篇期刊分区无法核验的文献中，PMID 42436722（纳米抗体可溶性表达）和PMID 42427444（环肽/nanobody CAR）最值得在期刊被JCR收录后追踪。

五、最终质量检查

每篇文献均有 PMID

总体评价：本周21篇Q1/Q2文献中，9篇A级（强烈推荐）、5篇B级（推荐关注）、7篇C级（相关但优先级较低，其中5篇为综述）。核心发现集中于VHH在免疫治疗、抗病毒、诊疗一体化和AI辅助设计方向的突破。

报告生成时间：2026年7月15日 | 自动化脚本执行 | 下次更新：2026年7月22日